4-(4-tert-butylphenyl)-1H-1,2,4-triazol-5-one | 1346234-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-tert-butylphenyl)-1H-1,2,4-triazol-5-one
• CAS: 1346234-99-8
• 化学式: C₁₂H₁₅N₃O
• 分子量: 217.271
• InChiKey: MHTVEWBLFXDUDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-tert-butylphenyl)-1H-1,2,4-triazol-5-one 在 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 1-(3-(4-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl) piperazin-1-yl)propyl)-4-(4-tert-butylphenyl)-1H-1,2,4-triazol-5(4H)-one
  参考文献：
  名称：

  Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism

  摘要：

  The incidence of life-threatening fungal infections is increasing dramatically. In an attempt to develop novel antifungal agents, our previously synthesized phenoxyalkylpiperazine triazole derivatives were used as lead structures for further optimization. By means of structure-based bioisosterism, triazolone was used as a new bioisostere of oxygen atom. This type of bioisosteric replacement can improve the water solubility without loss of hydrogen-bonding interaction with the target enzyme. A series of triazolone-containing triazoles were rationally designed and synthesized. As compared with fluconazole, several compounds showed higher antifungal activity with broader spectrum, suggesting their potential for further evaluations. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.03.019
• 作为产物：
  描述：

  1-Amino-3-(4-tert-butylphenyl)urea 、 醋酸甲脒 在 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(4-tert-butylphenyl)-1H-1,2,4-triazol-5-one
  参考文献：
  名称：

  Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism

  摘要：

  The incidence of life-threatening fungal infections is increasing dramatically. In an attempt to develop novel antifungal agents, our previously synthesized phenoxyalkylpiperazine triazole derivatives were used as lead structures for further optimization. By means of structure-based bioisosterism, triazolone was used as a new bioisostere of oxygen atom. This type of bioisosteric replacement can improve the water solubility without loss of hydrogen-bonding interaction with the target enzyme. A series of triazolone-containing triazoles were rationally designed and synthesized. As compared with fluconazole, several compounds showed higher antifungal activity with broader spectrum, suggesting their potential for further evaluations. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.03.019

文献信息

• PDE 10a Inhibitors for the Treatment of Type II Diabetes
  申请人：Janssen Pharmaceutica, NV

  公开号：US20140364414A1

  公开（公告）日：2014-12-11

  Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , L, and Q are defined herein.

  揭示了用于治疗2型糖尿病的化合物、组合物和方法。这些化合物由以下式（I）表示： 其中R1、R2、L和Q在此处定义。
• NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
  申请人：SANOFI

  公开号：US20180079720A1

  公开（公告）日：2018-03-22

  Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH) 2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH) 2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

  化合物的式子为(I):其中R1和R2代表氢或氘原子；R3代表氢原子或—COOH，—OH或—OPO(OH)2基团；R4代表氢原子或氟原子；R5代表氢原子或—OH基团；其中至少一个R3或R5不同于氢原子；当R3代表—COOH，—OH或—OPO(OH)2基团时，R5代表氢原子；当R5代表—OH基团时，R3和R4代表氢原子；R6从可选取的取代苯基，杂环芳基，环烷基和杂环烷基群中选择；化合物的制备和治疗用途为公式(I)的抑制剂和降解剂，特别适用于癌症治疗。
• JAK1 Inhibitors
  申请人：Anand Neel Kumar

  公开号：US20130165440A1

  公开（公告）日：2013-06-27

  JAK1 inhibitors of structural formula (I), wherein Ar 1 , Ar 2 , Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  本发明涉及结构式(I)的JAK1抑制剂，其中Ar1，Ar2，Q，W，X，Y和Z在说明书中定义，其药学上可接受的盐，组合物以及用于治疗疾病的化合物和组合物的用途。本发明还涉及化合物在制药方面的使用，特别是用于治疗疾病的制药。
• Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
  申请人：SANOFI

  公开号：US10570090B2

  公开（公告）日：2020-02-25

  Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

  式(I)化合物： 其中 R1 和 R2 代表氢原子或氘原子；R3 代表氢原子或-COOH、-OH 或-OPO(OH)2 基团；R4 代表氢原子或氟原子；R5 代表氢原子或-OH 基团；其中 R3 或 R5 中至少有一个不同于氢原子；当 R3 代表-COOH、-OH 或-OPO(OH)2 基团时，则 R5 代表氢原子；当 R5 代表-OH 基团时，则 R3 和 R4 代表氢原子；以及 R6 选自任选取代的苯基、杂芳基、环烷基和杂环烷基； 以及式（I）化合物作为雌激素受体抑制剂和降解剂的制备和治疗用途，特别是在癌症治疗中的用途。
• US9249163B2
  申请人：——

  公开号：US9249163B2

  公开（公告）日：2016-02-02